Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.
“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “We have big plans for the future beginning with our upcoming acquisition of Rozetta-Cell and are about to enter a long and substantial growth phase marked by advances in our science and intellectual property. Given the imminent nature of many of these transactions and breakthroughs, we have decided, in consultation with the financiers of Rozetta-Cell, that the best course of action for Power3 is to settle many of these lawsuits so that we can focus our attention exclusively on the acquisition of Rozetta-Cell and the development of our combined businesses after the merger.”
Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro�, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials.
Orofino Gold Corp. (ORFG.PK) engages in acquisition, exploration, and development of gold properties in Mexico and Colombia. The company has an option to acquire properties in the Sur de Bolivar Department of Colombia South America. Orofino Gold Corp. was formerly known as SNT Cleaning, Inc. and changed its name to Orofino Gold Corp. in December 2009. The company was founded in 2005 and is based in Central, Hong Kong.
In addition, Orofino has acquired a database comprised of exploration and mining results from previous operators who left when the global mining sector experienced a major downturn in the 1997-2000 time frame.
The second part of the Company’s strategy to become a recognized player in the Colombia mining sector was the acquisition of an interest in an operating mine. The Company has acquired a 55% interest in the La Azul/La Estrella property with the rights to acquire up to 80%.
The vision of Orofino Gold Corp.:
To become a good Joint Venture Partner
To become a premier Mid Tier precious metals mining operation in Colombia
To fast track first mine to commercial production.
Intrinsic, and essential, to this vision is the Company’s moral, ethical and social commitment to develop the communities related to the projects.
Amdocs Ltd. (NYSE:DOX) announced that Pelephone Communications, Ltd., an Israeli mobile service provider, has upgraded its systems to Amdocs Mediation 8 to support the growth in data usage and the quick rollout of new services.
Amdocs Limited, through its subsidiaries, provides software and services to the communications, media, and entertainment industry service providers worldwide. The company�s software systems support the full span of the customer lifecycle, including revenue management, customer management, service and resource management, personalized portal and value-added services, and portfolio management.
Tripp Levy PLLC recently announced an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Compellent Technologies Inc. (NYSE: CML) by Dell, Inc. in a cash transaction valued at for a total equity value of approximately $960 million, and aggregate purchase price of approximately $820 million, net of Compellent�s cash. Under the terms of the agreement, Compellent shareholders will receive $27.75 per share in cash for each share they own.
Compellent Technologies, Inc. develops, markets, and services enterprise-class network storage solutions in the United States and internationally. It offers Storage Center, a storage area network that enables users to store, recover, and manage data by combining software and hardware into a single integrated solution.
Texas Instruments Inc. (NYSE:TXN) introduced a new power management controller and driver for standard and logic-level N-channel MOSFETs used for low-voltage, secondary-side synchronous rectification. The UCC24610 Green Rectifier� controller improves power supply efficiency as much as five percent, and reduces primary-side power loss in 5-volt AC/DC adapters and bias supplies.
Texas Instruments Incorporated engages in the design and sale of semiconductors to electronics designers and manufacturers worldwide. Its Analog segment offers high-performance analog products comprising standard analog semiconductors, such as amplifiers, and power management semiconductors and line-powered systems.
No comments:
Post a Comment